In 115 postmenopausal women with vulvovaginal atrophy, with or without breast cancer, weekly 20 mg vaginal tamoxifen left the most troublesome symptom mild or absent at 3 months in 68.6% vs 9.1% with placebo (OR 21.76).
RCTn = 115
Nyback et al. Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen